Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
Article Abstract:
Paclitaxel, along with other chemotherapeutic agents, may be effective in slowing the progression of ovarian cancer and improving survival. A total of 386 women with incompletely removed stage III or stage IV ovarian cancer were assigned to receive six courses of either cisplatin and cyclophosphamide or cisplatin and paclitaxel. The cisplatin was administered at 75 milligrams per square meter of body-surface (mg/square meter), the cyclophosphamide at 750 mg/square meter, and the paclitaxel at 75 mg/square meter. The rate at which women responded to therapy was 60% in the cyclophosphamide group, and 73% in the paclitaxel group. Median survival time was 24 months in the cyclophosphamide group, and 38 months in the paclitaxel group. Median survival without disease progression was 13 months with cyclophosphamide and 18 months with paclitaxel. Side effects included loss of hair, reduced neutrophil levels, and poisoning of nerve tissue.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
Article Abstract:
Infusing cisplatin directly into the peritoneal cavity appears to prolong life in women with advanced ovarian cancer. Cisplatin is usually given intravenously. Researchers randomly assigned 546 women with advanced ovarian cancer to receive intravenous cyclophosphamide and intravenous cisplatin or intravenous cyclophosphamide and intraperitoneal cisplatin. The women receiving intraperitoneal cisplatin survived a median of 49 months, compared to the women receiving intravenous cisplatin, who survived a median of 41 months. Intraperitoneal cisplatin reduced the risk of death by 24% and produced fewer side effects.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer
Article Abstract:
The addition of cisplatin to chemotherapy for advanced cervical cancer appears to improve a woman's prognosis. Researchers randomly assigned 526 women with advanced cervical cancer to receive cisplatin alone, hydroxyurea alone, or cisplatin and hydroxyurea and fluorouracil. All the women also received radiation treatment. Cisplatin either alone or in combination reduced the risk of disease progression or death by almost half compared to hydroxyurea alone. Survival rates were also higher in the women who received cisplatin compared to those who received hydroxyurea alone.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. Postoperative irradiation with or without concomitant chemotheraphy for locally advanced head and neck cancer
- Abstracts: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
- Abstracts: Chronic parotitis: diagnosis and treatment. Drug-induced paraparotid fat deposition in patients with HIV: case reports
- Abstracts: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
- Abstracts: Association of weight loss and weight fluctuation with mortality among Japanese American men. Serum total cholesterol and mortality: confounding factors and risk modification in Japanese-American men